---
title: "Morgan Stanley Sticks to Their Hold Rating for Crispr Therapeutics AG (CRSP)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294841732.md"
description: "Morgan Stanley analyst Terence Flynn maintained a Hold rating on Crispr Therapeutics AG (CRSP) with a $60 price target. This follows a Hold from TD Cowen, while William Blair reiterated a Buy rating for the stock."
datetime: "2026-08-04T14:26:46.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294841732.md)
  - [en](https://longbridge.com/en/news/294841732.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294841732.md)
generator: "portal-rs"
---

# Morgan Stanley Sticks to Their Hold Rating for Crispr Therapeutics AG (CRSP)

In a report released today, Terence Flynn from Morgan Stanley maintained a Hold rating on Crispr Therapeutics AG, with a price target of $60.00.

### Claim 55% Off TipRanks

-   Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
-   Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

Flynn covers the Healthcare sector, focusing on stocks such as Biogen, Gilead Sciences, and Johnson & Johnson. According to TipRanks, Flynn has an average return of 10.0% and a 57.40% success rate on recommended stocks. 

In addition to Morgan Stanley, Crispr Therapeutics AG also received a Hold from TD Cowen’s Tyler Van Buren in a report issued yesterday. However, today, William Blair reiterated a Buy rating on Crispr Therapeutics AG (NASDAQ: CRSP).

### Related Stocks

- [CRSP.US](https://longbridge.com/en/quote/CRSP.US.md)
- [MS.US](https://longbridge.com/en/quote/MS.US.md)
- [BIIB.US](https://longbridge.com/en/quote/BIIB.US.md)
- [GILD.US](https://longbridge.com/en/quote/GILD.US.md)
- [JNJ.US](https://longbridge.com/en/quote/JNJ.US.md)
- [MS-O.US](https://longbridge.com/en/quote/MS-O.US.md)
- [MS-Q.US](https://longbridge.com/en/quote/MS-Q.US.md)
- [MS-E.US](https://longbridge.com/en/quote/MS-E.US.md)
- [MS-I.US](https://longbridge.com/en/quote/MS-I.US.md)
- [MS-L.US](https://longbridge.com/en/quote/MS-L.US.md)
- [MS-P.US](https://longbridge.com/en/quote/MS-P.US.md)
- [MS-A.US](https://longbridge.com/en/quote/MS-A.US.md)
- [MS-F.US](https://longbridge.com/en/quote/MS-F.US.md)
- [MS-K.US](https://longbridge.com/en/quote/MS-K.US.md)

## Related News & Research

- [Raiffeisen Bank International AG Buys Shares of 20,000 CRISPR Therapeutics AG $CRSP](https://longbridge.com/en/news/298128987.md)
- [Crispr Therapeutics Maintained at Buy as Lp(a) Program Prospects Support Unchanged $88 Price Target](https://longbridge.com/en/news/298221327.md)
- [CRISPR Therapeutics (CRSP) Stock May Look Rich Following Fresh CTX310 Data](https://longbridge.com/en/news/297413766.md)
- [Shah Wealth Advisors LLC Buys New Position in CRISPR Therapeutics AG $CRSP](https://longbridge.com/en/news/298108618.md)
- [CRISPR Therapeutics (NASDAQ:CRSP) Earns Market Outperform Rating from Citizens Jmp](https://longbridge.com/en/news/296922645.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**